Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©
Open Access
- 18 April 2024
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (6) , 1669-1682
Abstract
Introduction This was a multicenter, prospective, longitudinal, observational study involving eight Spanish tertiary hospitals to determine the interobserver reliability of an uveitis disease activity index, (UVEDAI) and assess its sensitivity to change in patients with receiving pharmacologic treatment. Methods Patients aged ≥ 18 years diagnosed with active noninfectious uveitis were included. A complete baseline assessment was performed by two ophthalmologists who determined ocular inflammatory activity using the UVEDAI index independently of each other. The principal ophthalmologist made a new visit at 4 weeks to determine the change in inflammatory activity. The interobserver reliability analysis was performed by calculating the intraclass correlation coefficient (ICC), with the values of the variables and the UVEDAI obtained by both ophthalmologists in the more active eye at the baseline visit. Sensitivity to change in the UVEDAI index was assessed at 4 weeks from the start of pharmacologic treatment by determining the clinically relevant change, defined as a change in UVEDAI of ≥ 0.8 points over baseline. The mean change between both measures was compared using the repeated-measures t-test. Results A total of 111 patients were included. In the interobserver reliability analysis, the ICC for the UVEDAI value was 0.9, and, when compared with the mean UVEDAI values obtained by the ophthalmologists, no statistically significant differences were found (p value > 0.05). As for the sensitivity to change in UVEDAI, statistically significant differences (p value = 0.00) were found for the mean values of the index compared with baseline. In all cases, the index value decreased by > 1 point at the 4-week visit. Conclusions The interobserver reliability of the UVEDAI was high in the total sample. Furthermore, the index was sensitive in determining the change in inflammatory activity after treatment. We believe that UVEDAI is a disease activity index that enables objective comparison of results in clinical practice and trials.Keywords
Funding Information
- Sociedad Española de Reumatología
This publication has 33 references indexed in Scilit:
- Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in UveitisOphthalmology and Therapy, 2023
- Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or PanuveitisOphthalmology, 2021
- Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With UveitisJAMA, 2019
- Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious UveitisOphthalmology, 2018
- Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious UveitisAmerican Journal of Ophthalmology, 2017
- Development of an activity disease score in patients with uveitis (UVEDAI)Rheumatology International, 2016
- Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximabJapanese Journal of Ophthalmology, 2014
- Advances in the diagnosis and immunotherapy for ocular inflammatory diseaseSeminars in Immunopathology, 2008
- The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical careBest Practice & Research Clinical Rheumatology, 2007
- Patterns of uveitis as a guide in making rheumatologic and immunologic diagnosesArthritis & Rheumatism, 1997